MCL1 and lymphoma: While this interest has resulted in advances in treatment of hematogenous cancers, particularly in the inhibition of Bcl-2 and Bcl-xL in lymphoma, effective inhibitor treatments of solid tumors remains a challenge, particularly the effective targeting of Mcl-1 [33].